Evidence map›Paper›PMID 34675248›Full record

ArticleScientific reports2021

Dual recombinase action in the normal and neoplastic mammary gland epithelium.

Patrick D Rädler, Kerry Vistisen, Aleata A Triplett, Rayane Dennaoui, Yong Li, Hridaya Shrestha, Rosa-Maria Ferraiuolo, Amalraj Thangasamy, Dieter Saur, Kay-Uwe Wagner

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Patrick D Rädler *Department of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, mail code EL01TM, Detroit, MI, 48201, USA.
Kerry Vistisen *Department of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, mail code EL01TM, Detroit, MI, 48201, USA.
Aleata A Triplett *Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE, 68198, USA.
Rayane DennaouiDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, mail code EL01TM, Detroit, MI, 48201, USA.
Yong LiDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, mail code EL01TM, Detroit, MI, 48201, USA.
Hridaya ShresthaDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, mail code EL01TM, Detroit, MI, 48201, USA.
Rosa-Maria FerraiuoloDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, mail code EL01TM, Detroit, MI, 48201, USA.
Amalraj ThangasamyDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, mail code EL01TM, Detroit, MI, 48201, USA.
Dieter SaurDepartment of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Kay-Uwe WagnerDepartment of Oncology, Wayne State University School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, 4100 John R, mail code EL01TM, Detroit, MI, 48201, USA. wagnerk@karmanos.org.
Wayne State University · USThe Barbara Ann Karmanos Cancer Institute · USKlinikum rechts der Isar · DEUniversity of Nebraska Medical Center · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · NCI · WAYNE STATE UNIVERSITY · PI Larry H Matherly · 1985 to 2026
$5.3M
JAK1 Signaling in Pancreatic Cancer Initiation and ProgressionR01CA202917 · NCI · WAYNE STATE UNIVERSITY · PI WAGNER, KAY-UWE · 2017 to 2021
$1.6M
Targeting the PTAP Domain of TSG101 in ERBB2-associated Mammary CancerR03CA219332 · NCI · WAYNE STATE UNIVERSITY · PI WAGNER, KAY-UWE · 2017 to 2018
$153k
NCI NIH HHS CA009476NCI NIH HHS CA009531NCI NIH HHS CA202917NCI NIH HHS P30 CA022453NCI NIH HHS R01 CA202917NCI NIH HHS R03 CA219332NCI NIH HHS T32 CA009476NCI NIH HHS T32 CA009531
6 · The paper itself

Abstract

We developed a transgenic mouse line that expresses the codon-optimized Flp recombinase under the control of the MMTV promoter in luminal epithelial cells of the mammary gland. In this report, we demonstrate the versatile applicability of the new MMTV-Flp strain to manipulate genes in a temporally and spatially controlled manner in the normal mammary gland, in luminal-type mammary tumors that overexpress ERBB2, and in a new KRAS-associated mammary cancer model. Although the MMTV-Flp is expressed in a mosaic pattern in the luminal epithelium, the Flp-mediated activation of a mutant Kras

Indexed as

Mammary Neoplasms, AnimalAnimalsDNA NucleotidyltransferasesEpitheliumErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticIntegrasesMammary Neoplasms, ExperimentalMammary Tumor Virus, MouseMiceMice, TransgenicPromoter Regions, GeneticProto-Oncogene Proteins p21(ras)TransgenesCre recombinaseDNA NucleotidyltransferasesErb-b2 Receptor Tyrosine KinasesFLP recombinaseIntegrasesProto-Oncogene Proteins p21(ras)

Identifiers

PMID34675248
PMCPMC8531329
OpenAlexW3205230535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.